Methods and compositions for treating cancer
Inventors
Auerbach, Alan H. • Belldegrun, Arie S. • de Bono, Johann
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10702540-B2
Publication Date
2020-07-07
Expiration Date
Abstract
Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17, 20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17, 20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.
Core Innovation
The invention relates to cancer treatment methods and compositions for a human, including the treatment of refractory prostate cancer. The described approach administers a therapeutically effective amount of at least two anti-cancer agents, including abiraterone acetate or a pharmaceutically acceptable salt thereof together with prednisolone.
The described combination further includes administering abiraterone acetate or a pharmaceutically acceptable salt with at least one additional therapeutic agent, including other anti-cancer agents and steroids. Representative steroids are glucocorticoids and corticosteroids such as prednisone, prednisolone, dexamethasone, and hydrocortisone, and representative anti-cancer agents include mitoxantrone, paclitaxel, and docetaxel.
The document also addresses use in refractory cancer contexts and includes combinations that incorporate hormonal ablation agents such as leuprolide, goserelin, and triptorelin. The inhibitor is described as a 17α-hydroxylase/C17,20-lyase inhibitor, with abiraterone acetate identified as a preferred example, and includes structural description, derivatives, salts, and unit dosage and composition examples.
Claims Coverage
The independent claim covers a method for treating refractory prostate cancer in a human by administering a therapeutically effective amount of at least two anti-cancer agents, with one inventive core combination feature comprising abiraterone acetate or a pharmaceutically acceptable salt plus prednisolone. Only one independent claim is provided in the supplied claim set.
Refractory prostate cancer treatment with abiraterone acetate plus prednisolone
A method for the treatment of a refractory prostate cancer in a human comprising administering to said human a therapeutically effective amount of at least two anti-cancer agents, wherein the at least two anti-cancer agents are abiraterone acetate or a pharmaceutically acceptable salt thereof and a prednisolone.
As provided, claim coverage centers on combination therapy for refractory prostate cancer using abiraterone acetate or a pharmaceutically acceptable salt and prednisolone, with dependent claims further refining the prednisolone form and dose constraints and characterizing prednisolone’s functional effect in relation to response.
Stated Advantages
Enhances the response of refractory prostate cancer to abiraterone acetate or a pharmaceutically acceptable salt thereof.
Documented Applications
Treatment of refractory prostate cancer in a human using a therapeutically effective combination of abiraterone acetate or a pharmaceutically acceptable salt and prednisolone.
Cancer treatment using an abiraterone acetate-based 17α-hydroxylase/C17,20-lyase inhibitor combination with additional therapeutic agents, including anti-cancer agents and steroids such as glucocorticoids and corticosteroids.
Treatment involving combination with hormonal ablation agents, including leuprolide, goserelin, and triptorelin.
Interested in licensing this patent?